The most common adverse effects probably related to dronabinol are dizziness, euphoria, paranoid reaction, somnolence, abnormal thinking, abdominal pain, nausea and vomiting.
Please read full prescribing information available at http://www.parpharm.com/products.
About Par Pharmaceutical
Par Pharmaceutical, Inc. develops, manufactures and markets generic drugs and innovative branded pharmaceuticals for specialty markets. For press release and other company information, visit http://www.parpharm.com.
Safe Harbor Statement
Certain statements in this press release constitute "forward-looking
statements" within the meaning of the Private Securities Litigation Reform
Act of 1995. To the extent any statements made in this news release contain
information that is not historical, these statements are essentially
forward- looking and, as such, are subject to risks and uncertainties,
including the extent and impact of litigation arising out of the accounting
issues described in the Company's filings with the Securities and Exchange
Commission (SEC), the difficulty of predicting FDA filings and approvals,
acceptance and demand for new pharmaceutical products, the impact of
competitive products and pricing, new product development and launch,
reliance on key strategic alliances, uncertainty of patent litigation filed
against the Company, availability of raw materials, the regulatory
environment, fluctuations in operating results and other risks and
uncertainties detailed from time to time in the Company's filings with the
SEC, such as the Company's reports on Form 10-K, Form 10-Q and Form 8-K,
and amendments thereto. Any forward-looking statements included
|SOURCE Par Pharmaceutical Companies, Inc.|
Copyright©2008 PR Newswire.
All rights reserved